Fulgent Genetics Expect 2024 Core Revenue Of Approximately $280M, With Non-GAAP Loss Improvement From Approximately ($1.05) Per Share To Approximately ($0.30) Per Share, Compared To Consensus Of $280.18M And $(0.92)/Share
Fulgent Genetics Expect 2024 Core Revenue Of Approximately $280M, With Non-GAAP Loss Improvement From Approximately ($1.05) Per Share To Approximately ($0.30) Per Share, Compared To Consensus Of $280.18M And $(0.92)/Share
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.